Literature DB >> 7826964

Bioactive tumour necrosis factor alpha in pre-eclamptic patients with and without the HELLP syndrome.

W Visser1, I Beckmann, H A Bremer, H L Lim, H C Wallenburg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7826964     DOI： 10.1111/j.1471-0528.1994.tb13587.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN： 0306-5456


× No keyword cloud information.
  11 in total

1.  The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy.

Authors:  Marc R Parrish; Sydney R Murphy; Sarah Rutland; Kedra Wallace; Katrin Wenzel; Gerd Wallukat; Sharon Keiser; Lillian Fournier Ray; Ralf Dechend; James N Martin; Joey P Granger; Babbette LaMarca
Journal:  Am J Hypertens       Date:  2010-04-29       Impact factor: 2.689

2.  Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia.

Authors:  Cissy Chenyi Zhou; Roxanna A Irani; Yingbo Dai; Sean C Blackwell; M John Hicks; Susan M Ramin; Rodney E Kellems; Yang Xia
Journal:  J Immunol       Date:  2011-04-11       Impact factor: 5.422

3.  Inhibition of T-cell activation attenuates hypertension, TNFα, IL-17, and blood-brain barrier permeability in pregnant rats with angiogenic imbalance.

Authors:  Cynthia Bean; Shauna-Kay Spencer; Teylor Bowles; Patrick B Kyle; Jan M Williams; Jacob Gibbens; Kedra Wallace
Journal:  Am J Reprod Immunol       Date:  2016-08-01       Impact factor: 3.886

4.  Effect of tumour necrosis factor-alpha and interleukin 1beta on endothelium-dependent relaxation in rat mesenteric resistance arteries in vitro.

Authors:  R Wimalasundera; S Fexby; L Regan; S A McG Thom; A D Hughes
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

5.  Impaired autophagy by soluble endoglin, under physiological hypoxia in early pregnant period, is involved in poor placentation in preeclampsia.

Authors:  Akitoshi Nakashima; Mikiko Yamanaka-Tatematsu; Naonobu Fujita; Keiichi Koizumi; Tomoko Shima; Toshiko Yoshida; Toshio Nikaido; Aikou Okamoto; Tamotsu Yoshimori; Shigeru Saito
Journal:  Autophagy       Date:  2013-01-15       Impact factor: 16.016

6.  Role of sex steroids in modulating tumor necrosis factor alpha-induced changes in vascular function and blood pressure.

Authors:  Babbette D LaMarca; Derrick L Chandler; Lee Grubbs; Jennifer Bain; Gerald R McLemore; Joey P Granger; Michael J Ryan
Journal:  Am J Hypertens       Date:  2007-11       Impact factor: 2.689

7.  Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia.

Authors:  Cissy Chenyi Zhou; Roxanna A Irani; Yujin Zhang; Sean C Blackwell; Tiejuan Mi; Jiaming Wen; Harnath Shelat; Yong-Jian Geng; Susan M Ramin; Rodney E Kellems; Yang Xia
Journal:  Circulation       Date:  2010-01-11       Impact factor: 29.690

Review 8.  Pathophysiology of hypertension in response to placental ischemia during pregnancy: a central role for endothelin?

Authors:  Babbette D LaMarca; Barbara T Alexander; Jeffery S Gilbert; Michael J Ryan; Mona Sedeek; Sydney R Murphy; Joey P Granger
Journal:  Gend Med       Date:  2008

9.  Maternal plasma concentrations of the soluble tumor necrosis factor receptor 2 are increased prior to the diagnosis of preeclampsia.

Authors:  Baha Sibai; Roberto Romero; Mark A Klebanoff; Madeline Murguia Rice; Steve Caritis; Marshall D Lindheimer; J Peter Van Dorsten; Mark Landon; Menachem Miodovnik; Mitchell Dombrowski; Paul Meis
Journal:  Am J Obstet Gynecol       Date:  2009-06       Impact factor: 8.661

10.  TNFα blockade reverses vascular and uteroplacental matrix metalloproteinases imbalance and collagen accumulation in hypertensive pregnant rats.

Authors:  Zongli Ren; Ning Cui; Minglin Zhu; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2021-10-01       Impact factor: 5.858
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.